Skip to main content
logo

HansBiomed Corporation (KOSDAQ:042520)

South Korea flag South Korea · Delayed Price · Currency is KRW
22,550
+1,800 (8.67%)
At close: Oct 1, 2026
Market Cap321.59B +58.3%
Revenue (ttm)124.81B +45.9%
Net Income-19.66B
EPS-1,433.17
Shares Out 14.26M
PE Ration/a
Forward PE14.37
Dividendn/a
Ex-Dividend Daten/a
Volume232,488
Open20,950
Previous Close20,750
Day's Range20,450 - 23,750
52-Week Range15,300 - 57,800
Beta1.99
Analystsn/a
Price Targetn/a
Est. EarningsDec 18, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1990
Employees 315
Stock Exchange KOSDAQ
Ticker Symbol 042520
Full Company Profile

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.

Financial Statements